美国高风险年轻男男性行为者频繁HIV筛查的成本效果
本研究基于青少年医学试验网络数据,用数学模拟评估从15岁起对高风险年轻男男性行为者(YMSM)进行每年、每6个月和每3个月HIV筛查的成本效果。结果显示,与现状相比,每3个月筛查可提高CD4计数和预期寿命,具成本效果(ICER 4500美元/QALY),并减少40%的原发传播。
要点
- 每3个月HIV筛查相比现状具成本效果(ICER 4500美元/QALY)。
- 每3个月筛查使30岁前原发传播减少40%。
- 所有筛查策略均提高诊断时CD4计数和预期寿命。
核心结论
- 对高风险YMSM,每3个月HIV筛查相比更低频率筛查可改善临床结局且具成本效果。
研究设计与样本
- 基于ATN数据的数学模拟,比较每年、每6个月和每3个月筛查与现状(年筛查率0.7-10.3%)。
主要发现
- 与现状相比,所有策略提高诊断时CD4计数(296至477-515 cells/µL)和15岁起质量调整预期寿命(44.4至48.3-48.7年)。
- 每3个月筛查相比现状ICER为4500美元/QALY,并使30岁前原发传播减少40%。
关键数值与推荐
- HIV发病率0.91-6.41/100PY,筛查接受率80%, linkage-to-care/ART启动率76%。
临床怎么用
- 对高风险YMSM可考虑每3个月HIV筛查以改善结局并减少传播。
局限性
- 结果对传播率最敏感,模型依赖已发表数据(YMSM特异性数据有限时用替代数据)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Of new HIV infections in the US, 20% occur among young men who have sex with men (YMSM, ages 13-24), but >50% of YMSM with HIV are unaware of their status. Using Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) data, we projected the clinical benefit and cost-effectiveness of frequent HIV screening among high-risk YMSM from age 15. METHODS: Using a mathematical simulation, we examined 3 screening strategies: Yearly, 6-monthly, and 3-monthly, each in addition to the Status quo (SQ, 0.7-10.3% screened/year, stratified by age). We used published data (YMSM-specific when available) including: HIV incidences (0.91-6.41/100PY); screen acceptance (80%), linkage-to-care/antiretroviral therapy (ART) initiation (76%), HIV transmission (0.3-86.1/100PY, by HIV RNA), monthly ART costs ($2290-$3780), and HIV per-screen costs ($38). Projected outcomes included CD4 count at diagnosis, primary HIV transmissions from ages 15-30, quality-adjusted life expectancy, costs, and incremental cost-effectiveness ratios (ICERs, $/quality-adjusted life-year saved [QALY]; threshold ≤$100 000/QALY). RESULTS: Compared to SQ, all strategies increased projected CD4 at diagnosis (296 to 477-515 cells/µL) and quality-adjusted life expectancy from age 15 (44.4 to 48.3-48.7 years) among YMSM acquiring HIV. Compared to SQ, all strategies increased discounted lifetime cost for the entire population ($170 800 to $178 100-$185 000/person). Screening 3-monthly was cost-effective (ICER: $4500/QALY) compared to SQ and reduced primary transmissions through age 30 by 40%. Results were most sensitive to transmission rates; excluding the impact of transmissions, screening Yearly was ≤$100 000/QALY (ICER: $70 900/QALY). CONCLUSIONS: For high-risk YMSM in the US, HIV screening 3-monthly compared to less frequent screening will improve clinical outcomes and be cost-effective.
引用
- Neilan AM, Bulteel AJB, Hosek SG, et al. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. Clin Infect Dis. 2021. PMID: 32730625. doi:10.1093/cid/ciaa1061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。